Diagnostics expansion Arbor Vita has a focus on early and accurate diagnosis with existing products in clinical studies addressing HPV-related cancers and infectious diseases, plus a COVID-19 IgG ELISA test launched in 2020, indicating a readiness to pursue expanded diagnostic offerings and companion tests.

Clinical pipeline With a pipeline of development-stage products in addition to marketed items, there are opportunities to approach AVC for collaborations, licensing, or joint development deals to advance new diagnostics or therapeutic strategies.

Private, mid-size Company size (11-50 employees) and private ownership suggest agility but also potential need for strategic partnerships and scalable distribution channels to accelerate growth beyond current market traction.

Global health focus Active emphasis on global health challenges and infectious diseases positions AVC as a potential customer or partner for large diagnostic platforms, contract manufacturing, and supply agreements to support broader deployment.

Financial potential Revenue range of 25 to 50 million indicates a growing company with room for expansion; sales opportunities may include expanded assay kits, testing services, platform integrations, and commercial collaborations with larger diagnostic distributors.